| |
Musolino, 2008 (trastuzumab)
| | |
Nested PCR-based allele-specific restriction analysis assay
|
|
G/G (V/V)
|
11
|
10.67
|
0.03
| |
|
G/T (V/F)
|
26
|
26.67
| | |
|
T/T (F/F)
|
17
|
16.67
| | |
| |
Tamura, 2011 (trastuzumab) (Neoadjuvant group)
| | |
Goldengate genotyping
|
|
G/G (V/V)
|
7
|
6.67
|
0.15
| |
|
G/T (V/F)
|
6
|
6.67
| | |
|
T/T (F/F)
|
2
|
1.67
| | |
| |
Tamura, 2011 (trastuzumab)(Metastatic group)
| | |
Goldengate genotyping
|
|
G/G (V/V)
|
15
|
15.78
|
0.36
| |
|
G/T (V/F)
|
17
|
15.44
| | |
|
T/T (F/F)
|
3
|
3.78
| | |
| |
Hurvitz, 2011 (trastuzumab)
| | |
Nested PCR followed by Sanger sequencing (confirmed by MassARRAY)
|
|
G/G (V/V)
|
169
|
137.61
|
16.45
| |
|
G/T (V/F)
|
471
|
533.78
| | |
|
T/T (F/F)
|
549
|
517.61
| | |
| |
Cartron, 2002 (rituximab)
| | |
Nested PCR followed by allele-specific restriction enzyme digestion
|
|
G/G (V/V)
|
10
|
9
|
0.34
| |
|
G/T (V/F)
|
22
|
24
| | |
|
T/T (F/F)
|
17
|
16
| | |
| |
Weng, 2003 (rituximab)
| | |
Nested PCR followed by allele-specific restriction enzyme digestion. (confirmed by direct sequencing)
|
|
G/G (V/V)
|
13
|
12.52
|
0.05
| |
|
G/T (V/F)
|
40
|
40.97
| | |
|
T/T (F/F)
|
34
|
33.52
| | |
| |
Persky, 2012 (rituximab)
| | |
TaqMAN SNP Assay
|
|
G/G (V/V)
|
5
|
7.04
|
1.45
| |
|
G/T (V/F)
|
29
|
24.92
| | |
|
T/T (F/F)
|
20
|
22.04
| | |
| |
Kim, 2006 (rituximab)
| | |
Nested PCR followed by allele-specific restriction enzyme digestion
|
|
G/G (V/V)
|
53
|
56.64
|
2.74
| |
|
G/T (V/F)
|
54
|
46.73
| | |
|
T/T (F/F)
|
6
|
9.64
| | |
| |
Dornan, 2010 (rituximab)
| | |
Allele-specific PCR with SYBR Green
|
|
G/G (V/V)
|
49
|
53.07
|
1.0
| |
|
G/T (V/F)
|
202
|
192.6
| | |
|
T/T (F/F)
|
168
|
172.7
| | |
| |
Ghesquieres, 2012 (rituximab)
| | |
TaqMAN SNP Assay with specific fluorescent dye–labeled (FAM and VIC) MGB probes
|
|
G/G (V/V)
|
68
|
66.96
|
0.04
| |
|
G/T (V/F)
|
215
|
217.09
| | |
|
T/T (F/F)
|
177
|
175.96
| | |
| |
Carlotti, 2007 (rituximab)
| | |
PCR with fluorescent labeled probes followed by melt curve analysis
|
|
G/G (V/V)
|
17
|
17.2
|
0.01
| |
|
G/T (V/F)
|
46
|
45.59
| | |
|
T/T (F/F)
|
30
|
30.2
| | |
| |
Prochazka, 2011 (rituximab)
| | |
Nested PCR followed by allele-specific restriction enzyme digestion
|
|
G/G (V/V)
|
7
|
9.44
|
1.42
| |
|
G/T (V/F)
|
43
|
38.11
| | |
|
T/T (F/F)
|
36
|
38.44
| | |
| |
Bibeau, 2009 (cetuximab)
| | |
PCR followed by multiplex allele-specific PCR (SYBR Green fluorescence)
|
|
G/G (V/V)
|
10
|
14.59
|
5.02
| |
|
G/T (V/F)
|
43
|
33.82
| | |
|
T/T (F/F)
|
15
|
19.59
| | |
| |
Etienne-Grimaldi, 2012 (cetuximab)
| | |
Nested PCR followed by allele-specific restriction enzyme digestion
|
|
G/G (V/V)
|
6
|
6.71
|
0.19
| |
|
G/T (V/F)
|
25
|
23.58
| | |
|
T/T (F/F)
|
20
|
20.71
| | |
| |
Zhang, 2007 (cetuximab)
| | |
Allele-specific PCR
|
|
G/G (V/V)
|
5
|
4.11
|
0.44
| |
|
G/T (V/F)
|
14
|
15.77
| | |
|
T/T (F/F)
|
16
|
15.11
| | |
| |
Zhang, 2010 (cetuximab)
| | |
PCR – restriction fragment length polymorphism technique
|
|
G/G (V/V)
|
23
|
17.27
|
8.11
| |
|
G/T (V/F)
|
21
|
32.47
| | |
|
T/T (F/F)
|
21
|
15.27
| | |
| |
Dahan, 2011 (cetuximab)
| | |
PCR – restriction fragment length polymorphism technique
|
|
G/G (V/V)
|
6
|
4.57
|
0.88
| |
|
G/T (V/F)
|
20
|
22.86
| | |
|
T/T (F/F)
|
30
|
28.57
| | |
| |
Paez, 2010 (cetuximab)
| | |
48.48 dynamic array (BioMark system)
|
|
G/G (V/V)
|
16
|
12.81
|
1.89
| |
|
G/T (V/F)
|
41
|
47.38
| | |
|
T/T (F/F)
|
47
|
43.81
| | |
